CYDY News and Press, CytoDyn Inc From 07/18/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Dr. Pourhassan and Mobeen Syed, M.D., M.S. will discuss the Company’s multi-pathway to exploring the many potential opportunities for leronlimab, including COVID-19 VANCOUVER, Washington, July 17, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn”...

CytoDyn news moves faster than I am able to follow. Over the last week in preparation for a Seeking Alpha article, I took meticulous notes on the 7/4/20 Nader Pourhassan [NP] interview with Dr. Been. Then, I moved on to do the same with NP's 7/9/20 Wall Street Reporter's Next Super Stock p...

CytoDyn ( OTCQB:CYDY +4.5% ) has filed a comprehensive listing application package with The Nasdaq Stock Market to request an uplisting of its common stock. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on the move Read more ...

VANCOUVER, Washington, July 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

Equillium Reports Positive Data for COVID-19 Drug Trial Equillium Inc. (EQ) reported positive data for its COVID-19 drug itolizumab. The data showed that the drug candidate was useful in lowering the risk of mortality in patients suffering from coronavirus. The results were declared by i...

The pitfalls of vaccines After my earlier article , I thought I’d endorse my belief that antiviral combination therapy rather than vaccines will be the way to manage the COVID-19 pandemic. Recently, an FDA vaccine official suggested an increased vaccine “threshold” ...

The FDA has issued a Refusal to File lette r to CytoDyn ( OTCQB:CYDY ) related to its marketing application seeking approval of the combination of leronlimab and HAART (highly active antiretroviral therapy) for highly treatment-experienced HIV patients. More news on: CytoDyn Inc., Healthc...

Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC) for ongoing Phase 3 study (severe/critical population) is planned for next week. Both results to be announced in Ju...

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...